Compare Mesoblast Limited (MESO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs MGM Resorts International — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while MGM Resorts International trades at $30.16 (market cap $7.55B). The key difference: MGM Resorts International is far larger — about 4.3× Mesoblast Limited's market cap, and MGM Resorts International pays a 0.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and MGM Resorts International for 91 Days on average.
| MESO | MGM | |
|---|---|---|
Market Cap | $1.75B | $7.55B |
Volume | 239,027 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $50.69 |
52-Week Low | $13.19 | $30.00 |
Typical Hold Time | 14 Days | 91 Days |
Enterprise Value | $1.83B | $34.85B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day, reflecting recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock is technically bearish with key support at $29, while fundamentals show mixed signals: revenue growth is steady but net income margin has compressed to 2.4% in 2025. Analyst consensus remains bullish with a $48.75 price target, though near-term sentiment is pressured by deal uncertainty.
The outlook hinges on MGM's ability to stabilize earnings and potentially pursue strategic alternatives like a bid for People Inc. Upside exists if management executes on value-unlocking initiatives, but risks include integration challenges, high debt levels, and macroeconomic sensitivity. The current price offers a discount to analyst targets, presenting a contrarian opportunity amid weak sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
